Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cancer Immunotherapy Market Analysis By Product (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies, Cancer Vaccines), By Cancer Type, And Segment Forecasts, 2014 - 2025 - Research and Markets

Research and Markets
Posted on: 28 Nov 17

The "Cancer Immunotherapy Market Analysis By Product (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies, Cancer Vaccines), By Cancer Type, And Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.

The global cancer immunotherapy market is expected to reach USD 118.8 billion by 2025

Increasing patient pool and higher mortality rate are boosting the need for cancer immunotherapy globally. However, lack of awareness and adverse effects associated with immune therapeutic drugs are restraining market growth.

Cancer immunotherapy has been emerging as a new avenue for revenue generation for pharmaceutical companies. In addition, adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting demand for immunotherapy. Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is expected to initiate introduction of advanced therapeutics in the market.

Furthermore, increase in number of approvals for new immunotherapeutic drugs is driving the global market. Introduction of new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their ability to provide better cancer treatment.

Monoclonal antibodies are the most widely used immunotherapeutic drugs globally. Development of monoclonal antibodies as effective immunotherapeutic options started after the approval of Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell lymphoblastic leukemia. Increasing investments in R&D pertaining to use of monoclonal bodies as naked antigen binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have resulted in discovery of new therapeutic options for cancer treatment. Technological advancements, such as radiation and nanoparticle therapies, are boosting the cancer immunotherapy market. Majority of cancer immunotherapy drugs have been used in treatment of non-small cell lung cancer, breast cancer, and prostate cancer.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Cancer Immunitherapy Market Variables, Trends & Scope

Chapter 4 Cancer Immunotherapy Market: Product Estimates & Trend Analysis

Chapter 5 Cancer Immunotherapy Market : Cancer Type Estimates and Trend Analysis

Chapter 6 Regional Estimates & Trend Analysis, by Product and Cancer Type

Chapter 7 Competitive Landscape

  • AstraZeneca
  • Amgen, Inc.
  • F. Hoffman-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/research/bn5sjb/cancer

View source version on businesswire.com: http://www.businesswire.com/news/home/20171128005750/en/

Business Wire
www.businesswire.com

Last updated on: 28/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.